{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T19:04:01Z","timestamp":1782155041280,"version":"3.54.5"},"reference-count":292,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jaci.2023.03.026","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:32:58Z","timestamp":1682350378000},"page":"1429-1447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Type 1 diabetes and inborn errors of immunity: Complete strangers or 2 sides of the same coin?"],"prefix":"10.1016","volume":"151","author":[{"given":"Gaia","family":"Mancuso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Bechi Genzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fierabracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Fousteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.03.026_bib1","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2023.03.026_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(13)60591-7","article-title":"Type 1 diabetes","volume":"383","author":"Atkinson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.03.026_bib3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1152\/physrev.00003.2010","article-title":"Type 1 diabetes: etiology, immunology, and therapeutic strategies","volume":"91","author":"van Belle","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jaci.2023.03.026_bib4","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2337\/dc09-0934","article-title":"Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1","volume":"32","author":"Orban","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2023.03.026_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2010.03.016","article-title":"Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis","volume":"32","author":"Husebye","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.03.026_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaut.2019.01.011","article-title":"Primary immunodeficiency and autoimmunity: a comprehensive review","volume":"99","author":"Amaya-Uribe","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jaci.2023.03.026_bib7","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41423-020-00626-z","article-title":"Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity","volume":"18","author":"Sogkas","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786241","article-title":"Endocrinopathies in inborn errors of immunity","volume":"12","author":"Takasawa","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib9","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/MOP.0000000000000833","article-title":"Autoimmunity as a continuum in primary immunodeficiency","volume":"31","author":"Walter","year":"2019","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jaci.2023.03.026_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dc19-0880","article-title":"Introducing the endotype concept to address the challenge of disease heterogeneity in type 1 diabetes","volume":"43","author":"Battaglia","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2023.03.026_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MED.0b013e32836313eb","article-title":"Insights into type 1 diabetes from the autoimmune polyendocrine syndromes","volume":"20","author":"Cheng","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jaci.2023.03.026_bib12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.3389\/fimmu.2018.02411","article-title":"Clinical, immunological, and molecular heterogeneity of 173 patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome","volume":"9","author":"Gambineri","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/83707","article-title":"X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy","volume":"27","author":"Wildin","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib15","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jaci.2018.10.026","article-title":"Tregopathies: monogenic diseases resulting in regulatory T-cell deficiency","volume":"142","author":"Cepika","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaci.2014.10.019","article-title":"Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA","volume":"135","author":"Charbonnier","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib18","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib19","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1056\/NEJM200106073442304","article-title":"Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation","volume":"344","author":"Baud","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib20","doi-asserted-by":"crossref","first-page":"215ra174","DOI":"10.1126\/scitranslmed.3007320","article-title":"CD4(+) T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer","volume":"5","author":"Passerini","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib21","doi-asserted-by":"crossref","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.18609\/cgti.2018.042","article-title":"Clinical applications of regulatory T cells in adoptive cell therapies","volume":"4","author":"Marshall","year":"2018","journal-title":"Cell Gene Ther Insights"},{"key":"10.1016\/j.jaci.2023.03.026_bib23","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.4049\/jimmunol.1100272","article-title":"Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function","volume":"188","author":"Garg","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2006.10.007","article-title":"CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes","volume":"119","author":"Caudy","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib25","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.4049\/jimmunol.177.5.2770","article-title":"Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency","volume":"177","author":"Cohen","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/db18-0627","article-title":"Type 1 diabetes in STAT protein family mutations: regulating the Th17\/Treg equilibrium and beyond","volume":"68","author":"Fabbri","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ng.3040","article-title":"Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease","volume":"46","author":"Flanagan","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib28","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2014-04-570101","article-title":"Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3","volume":"125","author":"Haapaniemi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.03.026_bib29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib30","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20110958","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib31","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jaci.2012.11.054","article-title":"Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome","volume":"131","author":"Uzel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib33","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib34","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib35","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib36","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.2337\/db17-0040","article-title":"Recessively inherited LRBA mutations cause autoimmunity presenting as neonatal diabetes","volume":"66","author":"Johnson","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cei.12997","article-title":"Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations","volume":"190","author":"Verma","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2015.11.004","article-title":"The crossroads of autoimmunity and immunodeficiency: lessons from polygenic traits and monogenic defects","volume":"137","author":"Grimbacher","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/imr.12721","article-title":"What did we learn from CTLA-4 insufficiency on the human immune system?","volume":"287","author":"Mitsuiki","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2023.03.026_bib40","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jpeds.2010.12.042","article-title":"STAT5b deficiency: an unsuspected cause of growth failure, immunodeficiency, and severe pulmonary disease","volume":"158","author":"Nadeau","year":"2011","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2023.03.026_bib41","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/pedi.12895","article-title":"Hematopoietic stem cell transplantation recovers insulin deficiency in type 1 diabetes mellitus associated with IPEX syndrome","volume":"20","author":"Yamauchi","year":"2019","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib42","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJMc2022226","article-title":"STAT1 Gain of function, type 1 diabetes, and reversal with JAK inhibition","volume":"383","author":"Chaimowitz","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib43","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.2337\/db06-1372","article-title":"Essential role for signal transducer and activator of transcription-1 in pancreatic beta-cell death and autoimmune type 1 diabetes of nonobese diabetic mice","volume":"56","author":"Kim","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/genes8020072","article-title":"Type 1 diabetes candidate genes linked to pancreatic islet cell inflammation and beta-cell apoptosis","volume":"8","author":"Storling","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jaci.2023.03.026_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fendo.2020.00119","article-title":"Advances in knowledge of candidate genes acting at the beta-cell level in the pathogenesis of T1DM","volume":"11","author":"Pang","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jaci.2023.03.026_bib46","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jaci.2023.03.026_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886736","article-title":"Functional impact of risk gene variants on the autoimmune responses in type 1 diabetes","volume":"13","author":"Gootjes","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib48","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11892-011-0223-x","article-title":"Genetics of the HLA region in the prediction of type 1 diabetes","volume":"11","author":"Noble","year":"2011","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jaci.2023.03.026_bib49","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1007\/s00125-021-05513-4","article-title":"DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life","volume":"64","author":"Thomas","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00125-021-05599-w","article-title":"Correction to: DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life","volume":"65","author":"Thomas","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib51","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/db20-0038","article-title":"Failed genetic protection: type 1 diabetes in the presence of HLA-DQB1\u221706:02","volume":"69","author":"Simmons","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib52","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(22)00159-0","article-title":"Type 1 diabetes in diverse ancestries and the use of genetic risk scores","volume":"10","author":"Redondo","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jaci.2023.03.026_bib53","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.2337\/db15-1690","article-title":"Type 1 diabetes genetic risk score: a novel tool to discriminate monogenic and type 1 diabetes","volume":"65","author":"Patel","year":"2016","journal-title":"diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2337\/dc15-1111","article-title":"A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults","volume":"39","author":"Oram","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2023.03.026_bib55","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00125-020-05115-6","article-title":"Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis","volume":"63","author":"Leete","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib56","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00125-020-05298-y","article-title":"Presumption of guilt for T cells in type 1 diabetes: lead culprits or partners in crime depending on age of onset?","volume":"64","author":"Carre","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib57","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00125-017-4284-5","article-title":"The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes","volume":"60","author":"Bloem","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib58","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.clim.2017.09.021","article-title":"Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes","volume":"183","author":"Hanley","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib59","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc15-1765","article-title":"Altered peripheral B-lymphocyte subsets in type 1 diabetes and latent autoimmune diabetes in adults","volume":"39","author":"Deng","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2023.03.026_bib60","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cei.13332","article-title":"A study of 51 subtypes of peripheral blood immune cells in newly diagnosed young type 1 diabetes patients","volume":"198","author":"Oras","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib61","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.immuni.2019.04.011","article-title":"Follicular helper cell biology: a decade of discovery and diseases","volume":"50","author":"Crotty","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.03.026_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864949","article-title":"Providing a helping hand: metabolic regulation of T follicular helper cells and their association with disease","volume":"13","author":"Mayberry","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib63","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1172\/JCI76238","article-title":"Follicular helper T cell signature in type 1 diabetes","volume":"125","author":"Kenefeck","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.03.026_bib64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1096\/fj.201901637R","article-title":"Follicular helper T cells in type 1 diabetes","volume":"34","author":"Shao","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.jaci.2023.03.026_bib65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41577-022-00693-5","article-title":"The link between circulating follicular helper T cells and autoimmunity","volume":"22","author":"Walker","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib66","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","article-title":"Follicular helper T cells","volume":"34","author":"Vinuesa","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib67","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s00125-017-4221-7","article-title":"Germinal centre frequency is decreased in pancreatic lymph nodes from individuals with recent-onset type 1 diabetes","volume":"60","author":"Willcox","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110755","article-title":"Altered B cell homeostasis and Toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis","volume":"9","author":"Gianchecchi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2023.03.026_bib69","doi-asserted-by":"crossref","first-page":"22584","DOI":"10.3390\/ijms160922584","article-title":"Expression of PD-1 molecule on regulatory T lymphocytes in patients with insulin-dependent diabetes mellitus","volume":"16","author":"Perri","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.03.026_bib70","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.4049\/jimmunol.1003224","article-title":"CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game","volume":"187","author":"Long","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib71","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.4049\/jimmunol.1601118","article-title":"Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?","volume":"197","author":"Visperas","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib72","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2337\/diabetes.54.1.92","article-title":"Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes","volume":"54","author":"Lindley","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","article-title":"Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction","volume":"28","author":"Tang","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.03.026_bib74","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1084\/jem.20141030","article-title":"Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity","volume":"212","author":"Paterson","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib75","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.4049\/jimmunol.181.10.7350","article-title":"The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells","volume":"181","author":"Schneider","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib76","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2249.2008.03810.x","article-title":"Increased resistance to CD4+CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes","volume":"154","author":"Lawson","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib77","doi-asserted-by":"crossref","first-page":"19857","DOI":"10.1073\/pnas.0810713105","article-title":"The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors","volume":"105","author":"D'Alise","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.03.026_bib78","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00125-020-05176-7","article-title":"Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes?","volume":"63","author":"Mallone","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib79","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3389\/fimmu.2018.03079","article-title":"PI3K Orchestrates t follicular helper cell differentiation in a context dependent manner: implications for autoimmunity","volume":"9","author":"Preite","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib80","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbrc.2018.09.182","article-title":"CTLA-4 regulates T follicular regulatory cell differentiation and participates in intestinal damage caused by\u00a0spontaneous autoimmunity","volume":"505","author":"Chao","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jaci.2023.03.026_bib81","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jaci.2017.05.022","article-title":"Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation","volume":"141","author":"Alroqi","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib82","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3389\/fimmu.2019.00753","article-title":"Case study: mechanism for increased follicular helper T cell development in activated PI3K delta syndrome","volume":"10","author":"Thauland","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib83","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1084\/jem.20170901","article-title":"Deficiency in T follicular regulatory cells promotes autoimmunity","volume":"215","author":"Fu","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib84","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3389\/fimmu.2020.01042","article-title":"Editorial: Follicular helper T cells in immunity and autoimmunity","volume":"11","author":"Cicalese","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2019.108319","article-title":"Reduced PD-1 expression on circulating follicular and conventional FOXP3(+) Treg cells in children with new onset type 1 diabetes and autoantibody-positive at-risk children","volume":"211","author":"Vecchione","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib86","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41574-020-00443-4","article-title":"Type 1 diabetes mellitus as a disease of the beta-cell (do not blame the immune system?)","volume":"17","author":"Roep","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jaci.2023.03.026_bib87","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2009.21","article-title":"The role of inflammation in insulitis and beta-cell loss in type 1 diabetes","volume":"5","author":"Eizirik","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jaci.2023.03.026_bib88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/ng0397-293","article-title":"The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes","volume":"15","author":"Pugliese","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib89","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ng1323","article-title":"A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes","volume":"36","author":"Bottini","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib90","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ng0397-289","article-title":"Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus","volume":"15","author":"Vafiadis","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib91","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s10875-021-00980-1","article-title":"The ever-increasing array of novel inborn errors of immunity: an interim update by the IUIS committee","volume":"41","author":"Tangye","year":"2021","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.753978","article-title":"Monogenic adult-onset inborn errors of immunity","volume":"12","author":"Staels","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib93","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.3389\/fimmu.2017.01740","article-title":"Common variable immunodeficiency non-infectious disease endotypes redefined using unbiased network clustering in large electronic datasets","volume":"8","author":"Farmer","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib94","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jaci.2009.03.030","article-title":"TH17 cells and regulatory T cells in primary immunodeficiency diseases","volume":"123","author":"Ochs","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib95","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/BOR.0b013e32831cb939","article-title":"Rheumatologic and autoimmune manifestations of primary immunodeficiency disorders","volume":"21","author":"Goyal","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaci.2023.03.026_bib96","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s10875-019-00737-x","article-title":"Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"40","author":"Tangye","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib97","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1210\/jcem.83.4.4682","article-title":"Clinical review 93: autoimmune polyglandular syndrome type 1","volume":"83","author":"Betterle","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2023.03.026_bib98","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1056\/NEJM199006283222601","article-title":"Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients","volume":"322","author":"Ahonen","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib99","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00005792-198109000-00003","article-title":"Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes","volume":"60","author":"Neufeld","year":"1981","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaci.2023.03.026_bib100","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/hmg\/5.7.1075","article-title":"The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry","volume":"5","author":"Nistico","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib101","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/diacare.29.03.06.dc05-1531","article-title":"Age at onset of childhood-onset type 1 diabetes and the development of end-stage renal disease: a nationwide population-based study","volume":"29","author":"Svensson","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2023.03.026_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.540718","article-title":"Neonatal diabetes mellitus","volume":"8","author":"Beltrand","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2023.03.026_bib103","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2567.2008.03017.x","article-title":"Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens","volume":"126","author":"Curtis","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2023.03.026_bib104","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/cei.12024","article-title":"Anti-cytokine autoantibodies suggest pathogenetic links with autoimmune regulator deficiency in humans and mice","volume":"171","author":"Karner","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17071106","article-title":"Type 1 Diabetes in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED): a \"rare\" manifestation in a \"rare\" disease","volume":"17","author":"Fierabracci","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.03.026_bib106","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1210\/jc.2005-2611","article-title":"Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"91","author":"Perheentupa","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2023.03.026_bib107","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000369682","article-title":"Increased levels of type 1 interferon in a type 1 diabetic mouse model induce the elimination of B cells from the periphery by apoptosis and increase their retention in the spleen","volume":"35","author":"Badr","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.jaci.2023.03.026_bib108","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cell.2016.06.024","article-title":"AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies","volume":"166","author":"Meyer","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2023.03.026_bib109","first-page":"1488","article-title":"Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I","volume":"81","author":"Tuomi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2023.03.026_bib110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/humu.1178","article-title":"Novel AIRE mutations and P450 cytochrome autoantibodies in Central and Eastern European patients with APECED","volume":"18","author":"Cihakova","year":"2001","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jaci.2023.03.026_bib111","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1365-2133.2006.07166.x","article-title":"Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome","volume":"154","author":"Collins","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2023.03.026_bib112","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1399-0004.2009.01278.x","article-title":"Novel and recurrent mutations in the AIRE gene of autoimmune polyendocrinopathy syndrome type 1 (APS1) patients","volume":"76","author":"Faiyaz-Ul-Haque","year":"2009","journal-title":"Clin Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib113","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00251-006-0088-3","article-title":"Association analysis of the AIRE and insulin genes in Finnish type 1 diabetic patients","volume":"58","author":"Turunen","year":"2006","journal-title":"Immunogenetics"},{"key":"10.1016\/j.jaci.2023.03.026_bib114","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/gene.2010.33","article-title":"Risk of autoimmune diabetes in APECED: association with short alleles of the 5'insulin VNTR","volume":"11","author":"Paquette","year":"2010","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaci.2023.03.026_bib115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1744-313X.2006.00643.x","article-title":"The role of the IDDM2 locus in the susceptibility of UK APS1 subjects to type 1 diabetes mellitus","volume":"34","author":"Adamson","year":"2007","journal-title":"Int J Immunogenet"},{"key":"10.1016\/j.jaci.2023.03.026_bib116","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1210\/jcem.87.6.8564","article-title":"AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype","volume":"87","author":"Halonen","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2023.03.026_bib117","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/nyas.14106","article-title":"Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance","volume":"1461","author":"Martinov","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaci.2023.03.026_bib118","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1440-1711.2002.01097.x","article-title":"Possible mechanism for the alpha subunit of the interleukin-2 receptor (CD25) to influence interleukin-2 receptor signal transduction","volume":"80","author":"Ellery","year":"2002","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jaci.2023.03.026_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.669298","article-title":"IL-2 signaling axis defects: how many faces?","volume":"9","author":"Consonni","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2023.03.026_bib120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clim.2019.02.003","article-title":"CD25 deficiency: a new conformational mutation prevents the receptor expression on cell surface","volume":"201","author":"Vignoli","year":"2019","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib121","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.beem.2010.09.003","article-title":"STAT5b deficiency: lessons from\u00a0STAT5b gene mutations","volume":"25","author":"Hwa","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2023.03.026_bib122","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41467-018-04521-0","article-title":"Dominant-negative STAT5B mutations cause growth hormone insensitivity with short stature and mild immune dysregulation","volume":"9","author":"Klammt","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2023.03.026_bib123","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2014-09-602763","article-title":"Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations","volume":"125","author":"Milner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.03.026_bib124","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/ni.3753","article-title":"BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency","volume":"18","author":"Afzali","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib125","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2609737","article-title":"The critical role of Bach2 in shaping the balance between CD4(+) T cell subsets in immune-mediated diseases","volume":"2019","author":"Yang","year":"2019","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jaci.2023.03.026_bib126","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1210\/jc.2016-2368","article-title":"A variant in the BACH2 gene is associated with susceptibility to autoimmune Addison's disease in humans","volume":"101","author":"Pazderska","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2023.03.026_bib127","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1002\/art.38183","article-title":"Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data","volume":"65","author":"McAllister","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2023.03.026_bib128","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/jdi.13057","article-title":"Variants in the BACH2 and CLEC16A gene might be associated with susceptibility to insulin-triggered type 1 diabetes","volume":"10","author":"Onuma","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jaci.2023.03.026_bib129","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.2337\/db13-1443","article-title":"BACH2, a candidate risk gene for type 1 diabetes, regulates apoptosis in pancreatic beta-cells via JNK1 modulation and crosstalk with the candidate gene PTPN2","volume":"63","author":"Marroqui","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib130","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib131","article-title":"Inborn errors of immunity and their phenocopies: CTLA4 and PD-1","volume":"12","author":"Hao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.03.026_bib133","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib134","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.20071477","article-title":"The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells","volume":"205","author":"Haxhinasto","year":"2008","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib135","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib136","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.1073\/pnas.1201131109","article-title":"Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in\u00a0vivo","volume":"109","author":"Gotot","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2023.03.026_bib137","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41591-021-01388-5","article-title":"Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child","volume":"27","author":"Ogishi","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib138","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/cei.13600","article-title":"Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review","volume":"205","author":"Jamee","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib139","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.03.026_bib140","doi-asserted-by":"crossref","first-page":"46478","DOI":"10.1074\/jbc.M206894200","article-title":"A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele","volume":"277","author":"Anjos","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2023.03.026_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00251-002-0429-9","article-title":"A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1\u00a0+49) alters T-cell activation","volume":"54","author":"Maurer","year":"2002","journal-title":"Immunogenetics"},{"key":"10.1016\/j.jaci.2023.03.026_bib142","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.4049\/jimmunol.165.11.6606","article-title":"CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves' disease","volume":"165","author":"Kouki","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib143","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaci.2015.09.025","article-title":"The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency","volume":"137","author":"Gamez-Diaz","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib144","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/pai.12735","article-title":"Clinical, immunologic, molecular analyses and outcomes of iranian patients with LRBA deficiency: a longitudinal study","volume":"28","author":"Azizi","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib145","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1126\/science.282.5397.2263","article-title":"Molecular basis of T cell inactivation by CTLA-4","volume":"282","author":"Lee","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib146","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10875-015-0224-7","article-title":"Spectrum of phenotypes associated with mutations in LRBA","volume":"36","author":"Alkhairy","year":"2016","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib147","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.aaa1663","article-title":"AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy","volume":"349","author":"Lo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib148","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.4049\/jimmunol.166.7.4586","article-title":"Identification of a novel lipopolysaccharide-inducible gene with key features of both A\u00a0kinase anchor proteins and chs1\/beige proteins","volume":"166","author":"Wang","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib149","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00125-018-4551-0","article-title":"A type 1 diabetes genetic risk score can discriminate monogenic autoimmunity with diabetes from early-onset clustering of polygenic autoimmunity with diabetes","volume":"61","author":"Johnson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib150","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00125-020-05276-4","article-title":"Type 1 diabetes can present before the age of 6 months and is characterised by autoimmunity and rapid loss of beta cells","volume":"63","author":"Johnson","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib151","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/pedi.13426","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: the diagnosis and management of monogenic diabetes in children and adolescents","volume":"23","author":"Greeley","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib152","first-page":"612","article-title":"Understanding the mechanism of diabetes mellitus in a LRBA-deficient patient","volume":"11","author":"Hawari","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.jaci.2023.03.026_bib153","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib154","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/pai.12585","article-title":"Activated PI3Kdelta syndrome type 2: Two patients, a novel mutation, and review of the literature","volume":"27","author":"Olbrich","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib155","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib156","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib157","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.652405","article-title":"Activated pi3kinase delta syndrome-a multifaceted disease","volume":"9","author":"Thouenon","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2023.03.026_bib158","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fimmu.2018.00338","article-title":"Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome","volume":"9","author":"Condliffe","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib159","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib160","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fped.2019.00353","article-title":"Inborn errors of immunity with immune dysregulation: from bench to bedside","volume":"7","author":"Delmonte","year":"2019","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jaci.2023.03.026_bib161","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ajhg.2012.04.015","article-title":"Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity","volume":"90","author":"Lopez-Herrera","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib162","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2119\/molmed.2011.00195","article-title":"Selective IgA deficiency in autoimmune diseases","volume":"17","author":"Wang","year":"2011","journal-title":"Mol Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib163","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12016-019-08756-7","article-title":"The epidemiology and clinical manifestations of autoimmunity in selective IgA deficiency","volume":"58","author":"Odineal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib164","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/(SICI)1096-9136(199801)15:1<38::AID-DIA520>3.0.CO;2-L","article-title":"Coeliac disease in children and adolescents with IDDM: clinical characteristics and response to gluten-free diet","volume":"15","author":"Acerini","year":"1998","journal-title":"Diabet Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib165","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF00253738","article-title":"Immunoglobulin levels, immunodeficiency and HLA in type 1 (insulin-dependent) diabetes mellitus","volume":"23","author":"Hoddinott","year":"1982","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib166","first-page":"215","article-title":"Defect in IgA secretion and in IgA specific suppressor cells in patients with selective IgA deficiency","volume":"89","author":"Waldmann","year":"1976","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.jaci.2023.03.026_bib167","first-page":"306","article-title":"IgA synthesis by peripheral blood mononuclear cells from normal and selectively IgA deficient subjects","volume":"38","author":"King","year":"1979","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib168","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0090-1229(77)90062-9","article-title":"Prevalence of HLA-A1 and HLA-B8 antigens in selective IgA deficiency","volume":"7","author":"Ambrus","year":"1977","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.jaci.2023.03.026_bib169","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1086\/302326","article-title":"Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition","volume":"64","author":"Vorechovsky","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s10875-009-9336-2","article-title":"IgA deficiency and the MHC: assessment of relative risk and microheterogeneity within the HLA A1 B8, DR3 (8.1) haplotype","volume":"30","author":"Mohammadi","year":"2010","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib171","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000441723","article-title":"Negativity for specific autoantibodies in patients with type 1 diabetes that developed on a background of common variable immunodeficiency","volume":"168","author":"Milota","year":"2015","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib172","doi-asserted-by":"crossref","first-page":"14","DOI":"10.18176\/jiaci.0388","article-title":"Common variable immunodeficiency: epidemiology, pathogenesis, clinical manifestations, diagnosis, classification, and management","volume":"30","author":"Yazdani","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib173","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0091-6749(89)90324-2","article-title":"Type I diabetes in an adolescent with common variable immunodeficiency","volume":"84","author":"Moffitt","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib174","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jaci.2020.01.046","article-title":"Plasma protein profiling reflects T(H)1-driven immune dysregulation in common variable immunodeficiency","volume":"146","author":"Hultberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00422093","article-title":"Humoral immunodeficiency to bacterial antigens in patients with juvenile onset diabetes mellitus","volume":"12","author":"Ludwig","year":"1976","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib176","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000135694","article-title":"Progression of selective IgA deficiency to common variable immunodeficiency","volume":"147","author":"Aghamohammadi","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib177","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.952715","article-title":"Natural history of type 1 diabetes on an immunodysregulatory background with genetic alteration in B-cell activating factor receptor: a case report","volume":"13","author":"Di Lorenzo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib178","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa010465","article-title":"Development of type 1 diabetes despite severe hereditary B-cell deficiency","volume":"345","author":"Martin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib179","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1615\/CritRevImmunol.2014009988","article-title":"Mechanism of activation-induced cell death of T cells and regulation of FasL expression","volume":"34","author":"Arakaki","year":"2014","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib180","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/1744666X.2021.1978842","article-title":"Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS)","volume":"17","author":"Lambert","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib181","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.bj.2021.04.005","article-title":"Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes","volume":"44","author":"Gamez-Diaz","year":"2021","journal-title":"Biomed J"},{"key":"10.1016\/j.jaci.2023.03.026_bib182","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3324\/haematol.2010.030395","article-title":"Autoimmune lymphoproliferative syndrome: a multifactorial disorder","volume":"95","author":"Rieux-Laucat","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jaci.2023.03.026_bib183","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ymthe.2017.03.018","article-title":"Evolving gene therapy in primary immunodeficiency","volume":"25","author":"Thrasher","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2023.03.026_bib184","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2337\/diabetes.50.3.483","article-title":"Defective function of Fas in patients with type 1 diabetes associated with other autoimmune diseases","volume":"50","author":"DeFranco","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib185","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.12688\/f1000research.11545.1","article-title":"Autoimmune lymphoproliferative syndrome: more than a FAScinating disease","volume":"6","author":"Bride","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jaci.2023.03.026_bib186","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.it.2021.11.006","article-title":"Impact of human CD95 mutations on cell death and autoimmunity: a model","volume":"43","author":"Seyrek","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib187","doi-asserted-by":"crossref","unstructured":"Maccari ME, Schneider P, Smulski CR, Meinhardt A, Pinto F, Gonzalez-Granado LI, et al. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations [e-pub ahead of print]. J Allergy Clin Immunol https:\/\/doi.org\/10.1016\/j.jaci.2022.11.028. Accessed January 4, 2023.","DOI":"10.1016\/j.jaci.2022.11.028"},{"key":"10.1016\/j.jaci.2023.03.026_bib188","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ajhg.2010.01.028","article-title":"Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease","volume":"86","author":"Lohr","year":"2010","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib189","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1554","article-title":"Mutation in ITCH gene can cause syndromic multisystem autoimmune disease with acute liver failure","volume":"143","author":"Kleine-Eggebrecht","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaci.2023.03.026_bib190","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/cdd.2008.60","article-title":"Itch: a HECT-type E3 ligase regulating immunity, skin and cancer","volume":"15","author":"Melino","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jaci.2023.03.026_bib191","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib192","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib193","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jaci.2023.03.026_bib194","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2023.03.026_bib195","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10875-020-00847-x","article-title":"Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy","volume":"40","author":"Okada","year":"2020","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib196","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.immuni.2012.03.016","article-title":"Inborn errors of human JAKs and STATs","volume":"36","author":"Casanova","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.03.026_bib197","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10875-015-0214-9","article-title":"The extended clinical phenotype of 26 patients with chronic mucocutaneous candidiasis due to gain-of-function mutations in STAT1","volume":"36","author":"Depner","year":"2016","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib198","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/intimm\/dxz079","article-title":"Human gain-of-function STAT1 mutation disturbs IL-17 immunity in mice","volume":"32","author":"Tamaura","year":"2020","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib199","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jaci.2013.01.004","article-title":"Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival","volume":"131","author":"Romberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib200","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1074\/jbc.M110.162131","article-title":"STAT1 is a master regulator of pancreatic beta-cell apoptosis and islet inflammation","volume":"286","author":"Moore","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2023.03.026_bib201","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib202","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-016-0325-y","article-title":"Exploring autoimmunity in a cohort of children with genetically confirmed Aicardi-Goutieres syndrome","volume":"36","author":"Cattalini","year":"2016","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib203","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.03.026_bib204","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1172\/JCI81260","article-title":"Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production","volume":"125","author":"Brehm","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.03.026_bib205","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.ajhg.2018.04.010","article-title":"Heterozygous truncating variants in POMP escape nonsense-mediated decay and cause a unique immune dysregulatory syndrome","volume":"102","author":"Poli","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib206","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajmg.a.30732","article-title":"Autosomal dominant inheritance of spondyloenchondrodysplasia","volume":"135","author":"Bhargava","year":"2005","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jaci.2023.03.026_bib207","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29672","article-title":"Spondyloenchondrodysplasia with immune dysregulation: role of sirolimus","volume":"69","author":"Mathiyazhagan","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jaci.2023.03.026_bib208","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.1224026","article-title":"Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency","volume":"337","author":"Bogunovic","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib209","doi-asserted-by":"crossref","first-page":"e931","DOI":"10.1002\/ctm2.931","article-title":"ISG15 deficiency features a complex cellular phenotype that responds to treatment with itaconate and derivatives","volume":"12","author":"Waqas","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature13801","article-title":"Human intracellular ISG15 prevents interferon-alpha\/beta over-amplification and auto-inflammation","volume":"517","author":"Zhang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.03.026_bib211","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12969-022-00686-7","article-title":"Precision treatment of Singleton Merten syndrome with ruxolitinib: a case report","volume":"20","author":"Broser","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jaci.2023.03.026_bib212","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fgene.2017.00118","article-title":"RIG-I-Like Receptor signaling in Singleton-Merten syndrome","volume":"8","author":"Lu","year":"2017","journal-title":"Front Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib213","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jaip.2020.11.007","article-title":"Overview of STING-associated vasculopathy with onset in infancy (SAVI) among 21 patients","volume":"9","author":"Fremond","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.026_bib214","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/ard.2006.062984","article-title":"Development of additional autoimmune diseases in a multiethnic cohort of patients with systemic lupus erythematosus with reference to damage and mortality","volume":"66","author":"Chambers","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.03.026_bib215","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/jcm9030712","article-title":"New horizons in the genetic etiology of systemic lupus erythematosus and lupus-like disease: monogenic lupus and beyond","volume":"9","author":"Demirkaya","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib216","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41584-021-00739-3","article-title":"Treat-to-target in systemic lupus erythematosus: advancing towards its implementation","volume":"18","author":"Parra Sanchez","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaci.2023.03.026_bib217","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ebiom.2017.06.014","article-title":"Type 1 diabetes and type 1 interferonopathies: localization of a type 1 common thread of virus infection in the pancreas","volume":"22","author":"Jean-Baptiste","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaci.2023.03.026_bib218","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fendo.2017.00232","article-title":"Type I interferon is a catastrophic feature of the diabetic islet microenvironment","volume":"8","author":"Newby","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jaci.2023.03.026_bib219","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00299027","article-title":"Aberrant expression of class II major histocompatibility complex molecules by B cells and hyperexpression of class I major histocompatibility complex molecules by insulin containing islets in type 1 (insulin-dependent) diabetes mellitus","volume":"30","author":"Foulis","year":"1987","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174840","article-title":"Increased inflammation is associated with islet autoimmunity and type 1 diabetes in the Diabetes Autoimmunity Study in the Young (DAISY)","volume":"12","author":"Waugh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2023.03.026_bib221","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.2337\/db16-0616","article-title":"Expression of interferon-stimulated genes in insulitic pancreatic islets of patients recently diagnosed with type 1 diabetes","volume":"65","author":"Lundberg","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib222","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.2337\/db13-1777","article-title":"A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes","volume":"63","author":"Ferreira","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib223","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MED.0000000000000399","article-title":"Potential role of type I interferon in the pathogenic process leading to type 1 diabetes","volume":"25","author":"Qaisar","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.jaci.2023.03.026_bib224","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcv.2017.09.003","article-title":"Type 1 diabetes and viral infections: What is the relationship?","volume":"96","author":"Principi","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jaci.2023.03.026_bib225","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3390\/v11100885","article-title":"Viral infections and autoimmune disease: roles of\u00a0LCMV in delineating mechanisms of immune tolerance","volume":"11","author":"Fousteri","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.jaci.2023.03.026_bib226","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2016-000219","article-title":"Coxsackie-adenovirus receptor expression is enhanced in pancreas from patients with type 1 diabetes","volume":"4","author":"Hodik","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jaci.2023.03.026_bib227","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/pedi.12547","article-title":"Early childhood infections precede development of beta-cell autoimmunity and type 1 diabetes in children with HLA-conferred disease risk","volume":"19","author":"Mustonen","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib228","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/08916934.2013.796937","article-title":"Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: a meta-analysis","volume":"46","author":"Cen","year":"2013","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaci.2023.03.026_bib229","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cytogfr.2014.08.003","article-title":"Autoimmunity caused by constitutive activation of cytoplasmic viral RNA sensors","volume":"25","author":"Kato","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jaci.2023.03.026_bib230","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ng1800","article-title":"A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region","volume":"38","author":"Smyth","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaci.2023.03.026_bib231","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/ni.3766","article-title":"The A946T variant of the RNA sensor IFIH1 mediates an interferon program that limits viral infection but increases the risk for autoimmunity","volume":"18","author":"Gorman","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib232","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature04734","article-title":"Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses","volume":"441","author":"Kato","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.03.026_bib233","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/biom11081251","article-title":"Computational insights into the structural dynamics of MDA5 variants associated with Aicardi-Goutieres syndrome and Singleton-Merten syndrome","volume":"11","author":"Gosu","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.jaci.2023.03.026_bib234","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.1167728","article-title":"Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes","volume":"324","author":"Nejentsev","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib235","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaci.2018.06.012","article-title":"Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses","volume":"143","author":"Romberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib236","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.jaip.2018.01.015","article-title":"Partial RAG deficiency in a patient with varicella infection, autoimmune cytopenia, and anticytokine antibodies","volume":"6","author":"Goda","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.026_bib237","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI81722","article-title":"Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients","volume":"125","author":"Rigby","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.03.026_bib238","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2337\/dc13-0604","article-title":"Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment","volume":"37","author":"Orban","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jaci.2023.03.026_bib239","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib240","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00125-009-1644-9","article-title":"Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass","volume":"53","author":"Keymeulen","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.jaci.2023.03.026_bib241","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(11)60931-8","article-title":"Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial","volume":"378","author":"Sherry","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.03.026_bib242","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib243","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib244","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib245","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.03.026_bib246","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/annrheumdis-2021-221840","article-title":"Hypoglycaemia following JAK inhibitor treatment in patients with diabetes","volume":"81","author":"van Lint","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2023.03.026_bib247","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.588543","article-title":"The JAK1 selective inhibitor ABT 317 blocks signaling through interferon-gamma and common gamma chain cytokine receptors to reverse autoimmune diabetes in NOD mice","volume":"11","author":"Ge","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib248","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib249","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.2337\/db16-1250","article-title":"Repurposed JAK1\/JAK2 inhibitor reverses established autoimmune insulitis in NOD mice","volume":"66","author":"Trivedi","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib250","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13063-022-06356-z","article-title":"Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial","volume":"23","author":"Waibel","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.jaci.2023.03.026_bib251","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.add4947","article-title":"Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases","volume":"8","author":"Suzuki","year":"2023","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib252","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12832","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis","volume":"294","author":"Cappelli","year":"2020","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2023.03.026_bib253","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib254","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib255","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3389\/fendo.2020.00569","article-title":"Role of the PD-1\/PD-L1 dyad in the maintenance of pancreatic immune tolerance for prevention of type 1 diabetes","volume":"11","author":"Falcone","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jaci.2023.03.026_bib256","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1097\/CM9.0000000000000972","article-title":"Type 1 diabetes induced by immune checkpoint inhibitors","volume":"133","author":"Zhang","year":"2020","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jaci.2023.03.026_bib257","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1159\/000480634","article-title":"Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management","volume":"10","author":"Kapke","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jaci.2023.03.026_bib258","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.764138","article-title":"Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside","volume":"12","author":"Wu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jaci.2023.03.026_bib259","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.3389\/fimmu.2018.02306","article-title":"Immune checkpoints as therapeutic targets in autoimmunity","volume":"9","author":"Paluch","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib260","article-title":"Effectiveness and safety of JAK inhibitors in autoinflammatory diseases: a systematic review","volume":"9","author":"Boyadzhieva","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2023.03.026_bib261","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.717388","article-title":"Emerging place of JAK inhibitors in the treatment of inborn errors of immunity","volume":"12","author":"Hadjadj","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib262","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12016-021-08916-8","article-title":"Future of therapy for inborn errors of immunity","volume":"63","author":"Perez","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib263","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"activated PI3Kdelta syndrome\"-targeted therapy with the PI3Kdelta inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.03.026_bib264","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.tem.2009.03.002","article-title":"Akt and PTEN: beta-cell mass and pancreas plasticity","volume":"20","author":"Elghazi","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jaci.2023.03.026_bib265","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13578-020-00416-0","article-title":"Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours","volume":"10","author":"Xu","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1016\/j.jaci.2023.03.026_bib266","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/08916934.2012.732130","article-title":"Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice","volume":"46","author":"Durand","year":"2013","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaci.2023.03.026_bib267","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fimmu.2012.00256","article-title":"Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies","volume":"3","author":"Puri","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib268","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1586\/1744666X.2015.1044980","article-title":"The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease","volume":"11","author":"Burns","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib269","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib270","first-page":"777","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"368","author":"Gelfand","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib271","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJMc1215489","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"368","author":"Shimoni","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib272","first-page":"674","article-title":"Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all?","volume":"5","author":"Nagelkerke","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib273","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/0140-6736(93)92000-J","article-title":"Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura","volume":"342","author":"Debre","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.03.026_bib274","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: how does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"suppl\u00a01","key":"10.1016\/j.jaci.2023.03.026_bib275","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2249.2009.04022.x","article-title":"Intravenous immunoglobulins--understanding properties and mechanisms","volume":"158","author":"Durandy","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib276","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","article-title":"Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis","volume":"111","author":"Ephrem","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.03.026_bib277","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib278","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075199","article-title":"IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID","volume":"8","author":"Paquin-Proulx","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2023.03.026_bib279","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000083948","article-title":"Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success","volume":"136","author":"Durandy","year":"2005","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib280","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaip.2019.09.027","article-title":"Effective and safe treatment of a novel IL2RA deficiency with rapamycin","volume":"8","author":"Lai","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.03.026_bib281","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaci.2017.10.041","article-title":"Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: an international multicenter retrospective study","volume":"141","author":"Barzaghi","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib282","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7543","article-title":"PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and\u00a0progenitor cells reverses autoimmune diabetes","volume":"9","author":"Ben Nasr","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib283","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2020008187","article-title":"How I use allogeneic HSCT for adults with inborn errors of immunity","volume":"138","author":"Burns","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2023.03.026_bib284","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1007\/s10875-022-01278-6","article-title":"Retrospective, landmark analysis of long-term adult morbidity following allogeneic HSCT for inborn errors of immunity in infancy and childhood","volume":"42","author":"Day","year":"2022","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib285","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1126\/science.abh1657","article-title":"Strategies for durable beta cell replacement in type 1 diabetes","volume":"373","author":"Brusko","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jaci.2023.03.026_bib286","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.648408","article-title":"Low-dose IL-2 therapy in autoimmune and rheumatic diseases","volume":"12","author":"Grasshoff","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.03.026_bib287","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.147474","article-title":"The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes","volume":"6","author":"Dong","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2023.03.026_bib288","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1210\/clinem\/dgaa791","article-title":"Rapamycin plus vildagliptin to recover beta-cell function in long-standing type 1 diabetes: a double-blind, randomized trial","volume":"106","author":"Bolla","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jaci.2023.03.026_bib289","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.2337\/db12-0049","article-title":"Rapamycin\/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function","volume":"61","author":"Long","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jaci.2023.03.026_bib290","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.03.026_bib291","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.ekir.2022.03.030","article-title":"Study design: human leukocyte antigen class I molecule A(\u2217)02-chimeric antigen receptor regulatory T cells in renal transplantation","volume":"7","author":"Schreeb","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jaci.2023.03.026_bib292","doi-asserted-by":"crossref","unstructured":"Stucchi A, Maspes F, Montee-Rodrigues E, Fousteri G. Engineered Treg cells: the heir to the throne of immunotherapy [e-pub ahead of print]. J Autoimmun https:\/\/doi.org\/10.1016\/j.jaut.2022.102986. Accessed January 11, 2023.","DOI":"10.1016\/j.jaut.2022.102986"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492300427X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492300427X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:42:36Z","timestamp":1758793356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492300427X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":292,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S009167492300427X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.03.026","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type 1 diabetes and inborn errors of immunity: Complete strangers or 2 sides of the same coin?","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.03.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}